{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:15Z","timestamp":1781190855129,"version":"3.54.1"},"reference-count":91,"publisher":"Informa UK Limited","issue":"5-6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2026,4,13]]},"DOI":"10.1080\/1750743x.2026.2668210","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:11:03Z","timestamp":1777885863000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager"],"prefix":"10.1080","volume":"18","author":[{"given":"Prodromos","family":"Koutoukoglou","sequence":"first","affiliation":[{"name":"Theageneion Anticancer Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[{"name":"Henry Dunant Hospital Center","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21871"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2025.0560"},{"key":"e_1_3_9_6_1","unstructured":"National Comprehensive Cancer Network. Small cell lung cancer (Version 2.2026). [cited 2026 May 2]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2404873"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01011-6"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5821"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/BJC.1998.54"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2059"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90455-3"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.130"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1613"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.LUNGCAN.2022.03.003"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10637-022-01269-9"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.003"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00309-5"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1006\/SCDB.1998.0260"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-BIOPHYS-101920-082204"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472794"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15017"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-025-86237-Y"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAV0891"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4127"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1278"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2019-0877"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.729765"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRCLINONC.2017.71"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13402-019-00441-3"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAC9459"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105603"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30565-4"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040520"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26125838"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/334395a0"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE00920"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40364-025-00807-W"},{"key":"e_1_3_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2007.08.004"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/S12094-025-03980-4"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-024-02070-Z"},{"key":"e_1_3_9_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845"},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-SITC2023.1189"},{"key":"e_1_3_9_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2307980"},{"key":"e_1_3_9_52_1","unstructured":"Study Details | NCT03319940 | study Evaluating safety tolerability and pharmacokinetics (pk) of tarlatamab in adults with Small cell Lung Cancer (SCLC). | ClinicalTrials.Gov. [cited 2025 Nov 29]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03319940"},{"key":"e_1_3_9_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.8582"},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00553"},{"key":"e_1_3_9_56_1","unstructured":"Study Details | NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC). [ClinicalTrials.Gov Available online. [cited 2025 Nov 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05060016"},{"key":"e_1_3_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.057"},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_SUPPL.8015"},{"key":"e_1_3_9_59_1","unstructured":"Study Details | NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer. | ClinicalTrials.Gov [cited 2025 Nov 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05740566"},{"key":"e_1_3_9_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2502099"},{"key":"e_1_3_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.35738"},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2021.01.003"},{"key":"e_1_3_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104538"},{"key":"e_1_3_9_64_1","unstructured":"ESMO Congress. OncologyPRO 2025. [cited 2026 Mar 25]. Available from: https:\/\/oncologypro.esmo.org\/congress-resources\/esmo-congress-2025"},{"key":"e_1_3_9_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40425-018-0343-9"},{"key":"e_1_3_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2018.12.758"},{"key":"e_1_3_9_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020282"},{"key":"e_1_3_9_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/CURRONCOL30070467"},{"key":"e_1_3_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTOCRR.2025.100933"},{"key":"e_1_3_9_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00538"},{"key":"e_1_3_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2025.09.1164"},{"key":"e_1_3_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLLC.2025.03.006"},{"key":"e_1_3_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTOCRR.2025.100875"},{"key":"e_1_3_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.033"},{"key":"e_1_3_9_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.8088"},{"key":"e_1_3_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116038"},{"key":"e_1_3_9_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2025-SITC2025.0565"},{"key":"e_1_3_9_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2025-SITC2025.0844"},{"key":"e_1_3_9_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.1652"},{"key":"e_1_3_9_80_1","unstructured":"FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer | FDA Available online. [cited 2025 Dec 4]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer"},{"key":"e_1_3_9_81_1","unstructured":"EU\/3\/23\/2876 - Orphan Designation for Treatment of Small Cell Lung Cancer | European Medicines Agency (EMA). [cited 2025 Dec 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-23-2876"},{"key":"e_1_3_9_82_1","unstructured":"Amgen\u2019s IMDYLLTRA\u00ae\u25bc. (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom Available online. [cited 2025 Dec 4]. Available from: https:\/\/www.amgen.co.uk\/media\/news-release\/2025\/01\/amgens-imdylltra-tarlatamab-granted-a-conditional-marketing-authorisation-for-third-line-treatment-of-extensive-stage-small-cell-lung-cancer-in-the-united-kingdom"},{"key":"e_1_3_9_83_1","unstructured":"FDA Grants Traditional Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer | FDA Available online. [cited 2025 Dec 4]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer"},{"key":"e_1_3_9_84_1","unstructured":"Study Details | NCT07005128 | A Study Comparing Tarlatamab Durvalumab Carboplatin and Etoposide Versus Durvalumab Carboplatin and Etoposide in First-Line Extensive Stage Small-Cell Lung Cancer (ES-SCLC). ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT07005128"},{"key":"e_1_3_9_85_1","unstructured":"Study Details | NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311). ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07037758"},{"key":"e_1_3_9_86_1","unstructured":"Study Details | NCT06898957 | Study of Tarlatamab in Combination With YL201 With or Without Anti-Programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC). | ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06898957"},{"key":"e_1_3_9_87_1","unstructured":"Study Details | NCT06745323 | A Phase 2 Open-Label Randomized Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | ClinicalTrials.Gov [cited 2025 Dec 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06745323"},{"key":"e_1_3_9_88_1","unstructured":"Study Details | NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308). | ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06598306"},{"key":"e_1_3_9_89_1","unstructured":"Study Details | NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment | ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06502977"},{"key":"e_1_3_9_90_1","unstructured":"Study Details | NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC). | ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06117774"},{"key":"e_1_3_9_91_1","unstructured":"Study Details | NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum Etoposide and Durvalumab | ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06211036"},{"key":"e_1_3_9_92_1","unstructured":"Study Details | NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin Etoposide and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC). ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05361395"},{"key":"e_1_3_9_93_1","unstructured":"Study Details | NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC). ClinicalTrials.Gov. [cited 2025 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04885998"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1750743X.2026.2668210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:41:06Z","timestamp":1781188866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1750743X.2026.2668210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":91,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2026,4,13]]}},"alternative-id":["10.1080\/1750743X.2026.2668210"],"URL":"https:\/\/doi.org\/10.1080\/1750743x.2026.2668210","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}